Breaking Finance News

BioTelemetry, Inc. (NASDAQ:BEAT) has been downgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has downgraded BioTelemetry, Inc. (NASDAQ:BEAT) to Hold in a report released on Wednesday October 05, 2016.

Yesterday BioTelemetry, Inc. (NASDAQ:BEAT) traded 13.20% higher at $20.75. The company’s 50-day moving average is $19.01 and its 200-day moving average is $16.56. The last stock close price is up 25.31% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,815,781 shares of the stock were exchanged, up from an average trading volume of 448,658

See Chart Below

BioTelemetry, Inc. (NASDAQ:BEAT)

BioTelemetry, Inc. has a 52 week low of $8.74 and a 52 week high of $21.68 with a P/E ratio of 44.15 The company’s market cap is currently $0.

Brief Synopsis About BioTelemetry, Inc. (NASDAQ:BEAT)

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Healthcare, Technology, and Research. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers Mobile Cardiac Outpatient Telemetry service, which incorporates a lightweight patient-worn sensor attached to electrodes that capture two-channel electrocardiography (ECG) data, measuring electrical activity of the heart, on a compact wireless handheld monitor; event monitoring services to prescribe wireless event monitors, digital loop event monitors, memory loop event monitors, and non-loop event monitors; and a Holter monitor to cardiologists and electrophysiologists. The Technology segment focuses on the manufacture, engineering, and development of noninvasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices, including cardiac event monitors, digital Holter monitors, and mobile cardiac telemetry monitors. The Research Services segment provides cardiac monitoring, scientific consulting, and data management services for drug and medical device trials to pharmaceutical companies, medical device companies, and contract research and academic research organizations. Its centralized services include ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, imaging services, and expert reporting and statistical analysis. This segment also offers support services, such as project coordination, setup and management, equipment rental, data transfer, processing, and analysis, as well as 24/7 customer support and site training. The company is headquartered in Malvern, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.